Charles Matine insider trades: Bionik Laboratories (BNKL) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Charles reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 9, 2023 | BNKL | ↑ Buy | 180,555 | $0.60 | $108K | Direct | Jun 21, 2023 (12d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Charles Matine's insider trades
Charles Matine is a director at Bionik Laboratories (BNKL). Since Jun 9, 2023, Charles has reported 1 open-market purchase worth $108K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BNKL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.